Citius Oncology, Stock Market Value
| CTOR Stock | 0.94 0.06 6.00% |
| Symbol | Citius |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Citius Oncology,. If investors know Citius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Citius Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Citius Oncology, is measured differently than its book value, which is the value of Citius that is recorded on the company's balance sheet. Investors also form their own opinion of Citius Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is Citius Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Citius Oncology,'s market value can be influenced by many factors that don't directly affect Citius Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Citius Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Citius Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Citius Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Citius Oncology, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Citius Oncology,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Citius Oncology,.
| 12/09/2022 |
| 11/28/2024 |
If you would invest 0.00 in Citius Oncology, on December 9, 2022 and sell it all today you would earn a total of 0.00 from holding Citius Oncology, or generate 0.0% return on investment in Citius Oncology, over 720 days. Citius Oncology, is related to or competes with Phibro Animal, Procaps Group, Amphastar, Alkermes Plc, Evolus, Prestige Brand, and Pacira BioSciences,. Citius Oncology, is entity of United States More
Citius Oncology, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Citius Oncology,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Citius Oncology, upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 28.8 | |||
| Value At Risk | (10.29) | |||
| Potential Upside | 13.75 |
Citius Oncology, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Citius Oncology,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Citius Oncology,'s standard deviation. In reality, there are many statistical measures that can use Citius Oncology, historical prices to predict the future Citius Oncology,'s volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (1.13) | |||
| Total Risk Alpha | (1.92) | |||
| Treynor Ratio | (0.40) |
Citius Oncology, Backtested Returns
Citius Oncology, secures Sharpe Ratio (or Efficiency) of -0.12, which signifies that the company had a -0.12% return per unit of risk over the last 3 months. Citius Oncology, exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Citius Oncology,'s Standard Deviation of 6.71, mean deviation of 4.98, and Risk Adjusted Performance of (0.09) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.19, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Citius Oncology, will likely underperform. At this point, Citius Oncology, has a negative expected return of -0.79%. Please make sure to confirm Citius Oncology,'s jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Citius Oncology, performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
Citius Oncology, has no correlation between past and present. Overlapping area represents the amount of predictability between Citius Oncology, time series from 9th of December 2022 to 4th of December 2023 and 4th of December 2023 to 28th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Citius Oncology, price movement. The serial correlation of 0.0 indicates that just 0.0% of current Citius Oncology, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Citius Oncology, lagged returns against current returns
Autocorrelation, which is Citius Oncology, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Citius Oncology,'s stock expected returns. We can calculate the autocorrelation of Citius Oncology, returns to help us make a trade decision. For example, suppose you find that Citius Oncology, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Citius Oncology, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Citius Oncology, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Citius Oncology, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Citius Oncology, stock over time.
Current vs Lagged Prices |
| Timeline |
Citius Oncology, Lagged Returns
When evaluating Citius Oncology,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Citius Oncology, stock have on its future price. Citius Oncology, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Citius Oncology, autocorrelation shows the relationship between Citius Oncology, stock current value and its past values and can show if there is a momentum factor associated with investing in Citius Oncology,.
Regressed Prices |
| Timeline |
Pair Trading with Citius Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.8 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.72 | ESPR | Esperion Therapeutics | PairCorr |
| 0.7 | GILD | Gilead Sciences | PairCorr |
| 0.67 | FLGC | Flora Growth Corp | PairCorr |
| 0.6 | NBY | NovaBay Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Citius Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology, to buy it.
The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.